Navigation Links
Doctors Would Have 18% of High-Cholesterol Patients take New PCSK9 Inhibitor Drugs Today If FDA Approves Their Use, According to New Data from InCrowd
Date:6/12/2015

BOSTON, June 12, 2015 /PRNewswire/ -- A new survey completed within hours after the US Food & Drug Administration (FDA) hearings this week on two new PCSK9 inhibitors for reducing LDL cholesterol – the first new class of cholesterol-reducing drugs in decades – shows that doctors already are considering prescribing the drug to 18% of their patients, with many regarding the drug class as a "triumph of modern genetic engineering" – while also mindful of the drugs' cost, injectable-only delivery and lack of outcomes studies until 2017.

Data compiled by InCrowd, provider of real-time market intelligence to life sciences firms, represent the first analysis to quantify the expected shift in prescribing patterns represented by the new drug class.

If drugs such as Praluent™ (Sanofi-Regeneron) and Repatha™ (Amgen), which use injected monoclonal antibodies that inhibit the PCSK9 gene, achieve FDA clearance and became available on the market, the cardiologists and primary care physicians (PCPs) surveyed would immediately prescribe them to 7% of their patients as a replacement for their present medications, and to 11% of their patients as an addition to their therapeutic regimen. PCP sentiment was tallied because they represent the front line of cholesterol reduction and prescribe over half of drugs for treating high cholesterol. Survey respondents treated an average of 155 patients per month with high cholesterol in their practices.

Cardiologists were especially enthusiastic, with 76% saying they were very excited about the promise of PCSK9 inhibitors and on average planned to prescribe them for 10% of their patient base as a solo treatment and to 16% of their patients in addition to patients existing drug therapy. Most patients that the doctors would move to the new PCSK9 inhibitors are presently on statins such as Lipitor® (40%), Zocor® (24%) and Crestor® (23%). In a further sign of receptivity, 44% of cardiologists agreed that that would begin prescribing PCSK9 inhibitors as soon as they were approved, compared with 8% of PCPs.  In addition, 80% of cardiologists agreed that the clinical data to date has been shown to be impressively efficacious, compared with 32% of PCPs. 

"This is groundbreaking therapy – a real game-changer," said one doctor, while others said it would "revolutionize treatment for familial hypercholesterolemia" and give options to the statin-intolerant.

Patient cost was the #1 expected barrier to prescribing the drugs and was cited by 79% of respondents, with numerous comments on its "extreme pricing" similar to the early days of statins. Injection dosing was also a concern - "I cannot get the patients to take a pill, let alone an injectable for a condition that does not hurt them," one respondent said - although markedly less to cardiologists (24%) than PCPs (68%).  Interestingly the side effects and safety profile of the new drug category was not a significant issue for most doctors – in fact 20% of cardiologists cited side effects and safety as either a very low concern or no concern at all.

Regardless of FDA recommendations that Praluent and Repatha be used for harder to treat hetereozygous and homozygous familial hypercholesterolemia – results largely reiterated survey results on the types of conditions for which the physicians would prescribe PCSK9 inhibitors  -only 34% of all doctors surveyed believe PCSK9 inhibitors should be restricted to high-risk patients. Some 47% agreed that the PCSK9 inhibitors will satisfy previously unmet major needs in treating high cholesterol.

The survey included 113 physicians – 50 cardiologists and 63 PCPs – who are part of InCrowd's 1.8 million member "Crowd" of verified health care professionals.  Respondents answered the microsurvey during a several-hour time window Wednesday June 10, the majority of which were completed on physicians' mobile devices.  InCrowd's "Crowd" includes a host of other physician clinical specialties groups, nurses, hospital execs, and related life sciences experts. 

Although InCrowd assists 18 of the top 20 pharmas in the world plus other life science firms, InCrowd performed the survey as an independent assessment of prescriber sentiment and not at the request of any interested party.

"We're delighted to help quantify what the medical community thinks about this exciting new class of drugs, and the changes it may bring to the pharmaceutical industry," said Diane Hayes, co-founder and president of InCrowd.

About InCrowd 
InCrowd provides real-time market intelligence from validated experts, connecting life sciences companies directly with prescribers, patients, and other screened and validated healthcare professionals around the globe. Our easy-to-use proprietary web-based application allows clients to ask questions of specific respondent groups – "Crowds" – in the form of 2-5 minute online microsurveys. Responses are available in real time through a password-protected account, with the needed answers delivered within hours or days, not weeks and months.

Today, InCrowd has 18 of the top 20 pharmaceutical firms as customers and has just finished its most successful quarter in company history with a record number of answers delivered to clients. Through its powerful mobile microsurvey methodology and analytics engine, InCrowd enables clients to reach 1.8M healthcare professionals on-demand throughout the United States and around the globe in 20 languages. For more information, visit www.incrowdnow.com.

InCrowd Media Contacts 
Steven Handy
Director of Marketing
steven.handy@incrowdnow.com 
508.944.0787

Mary Kae Marinac 
PR Representative for InCrowd
mkm@mkmarinac.com 
978-685-3136

 


'/>"/>
SOURCE InCrowd
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada
2. Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids
3. California Medical Board Votes Unanimously To Support A Bill Requiring Doctors Check A Patients Prescription History Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog
4. Minna Life Survey: 57% of US Women Dont Get Pelvic Floor Information From Doctors
5. New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries
6. Diaton Tonometers Unique Transpalpebral Tonometry Capabilities Revealed at ASCRS ASOA Congress in San Diego to 1000s of Eye Doctors
7. Cancer screening rates improve, disparities shrink for patients with Blue Cross Blue Shield of Michigan patient-centered medical home doctors
8. 90% of NJ Residents Want More Information From Their Doctors About Potential Addictive Qualities of the Medications They Are Being Prescribed
9. Consumer Watchdog Calls for Release of Documents on Psychotropic Medication Prescribing in Foster Care, Ban on Big Pharma Payments to Doctors
10. Riordan Clinic IVC Academy Teaches Doctors About the Use of High Dose Vitamin C.
11. Biomet to Pay Over $6 Million to Resolve Whistleblower Claims That It Paid Kickbacks to Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2019)... ... ... Ginger Cove , Annapolis’ premier life care retirement community, is pleased to ... on Saturday, September 28 and Sunday, September 29, 2019. Men and women over the ... Cove and the West River Wickets' Courts. , Registration includes an opening reception on ...
(Date:5/21/2019)... ... 21, 2019 , ... Total Wellness expert Anolia O. has written the ultimate ... the key to unlocking hidden treasures to live the life they have always wanted. ... Life” Anolia provides readers with a better understanding of themselves and others, their journey ...
(Date:5/21/2019)... , ... May 21, 2019 , ... Bella Dental of ... its new dental practice website: https://www.belladentalnj.com/ . , According to Bella Dental founder ... has its own mobile app. It allows our office to provide our patients with ...
Breaking Medicine Technology:
(Date:5/21/2019)... Md. and GAITHERSBURG, Md. (PRWEB) , ... May 21, 2019 , ... ... from measles with a safe, proven and effective solution: vaccination. , Between January 1, ... 764 cases of measles across 23 states. Worryingly, this number includes a 60 case ...
(Date:5/21/2019)... ... May 21, 2019 , ... ... of collaborative robots for industrial applications, announced today it will be launching demonstration ... 2 (DIP2) in Dubai, UAE, and in Buseck, Germany. These demonstration centres will ...
(Date:5/21/2019)... ... May 21, 2019 , ... Pool and Spa News, ... system a Top 50 Product of 2019, recognizing market’s demand for the best, easiest ... was chosen from reader responses in Pool and Spa News’ 2019 New Products ...
(Date:5/21/2019)... ... May 21, 2019 , ... Peoria Ear, Nose ... County, says they are embracing a people-plus-technology strategy to help service a rapidly-growing ... As part of this strategy, they have partnered with Dallas-based Simple Interact ...
(Date:5/16/2019)... ... 2019 , ... Wambi, a leading workforce engagement company driving ... will be joining the company as Chief Clinical Officer. , In this role, ... features that create value for Wambi’s clients, nurse leaders and their teams. Dr. ...
Breaking Medicine News(10 mins):